MEK Inhibitors

MEK1

MEK2

MEK5

MEK

MAP2K4/MEK4

MEK Inhibitors, Antagonists & Activators

Product Name	MEK1	MEK2	MEK5	MEK	MAP2K4/MEK4	Purity
Trametinib	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM				99.93%
Mirdametinib	MEK1, Ki: 1 nM	MEK2, Ki: 1 nM		MEK, IC₅₀: 0.33 nM		99.95%
PD98059	MEK1, IC₅₀: 2-7 μM	MEK2, IC₅₀: 50 μM				99.94%
U0126	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM				98.57%
Selumetinib	MEK1, IC₅₀: 14 nM			MEK, IC₅₀: 12 nM		99.87%
CI-1040 hydrochloride	MEK1
U0126-EtOH	MEK1, IC₅₀: 70 nM	MEK2, IC₅₀: 60 nM				99.41%
Cobimetinib	MEK1, IC₅₀: 4.2 nM					99.81%
Binimetinib				MEK, IC₅₀: 12 nM		99.31%
C16-PAF				MEK		99.85%
Isorhamnetin	MEK1					99.94%
Avutometinib				MEK, IC₅₀: 160 nM		99.02%
Trametinib (DMSO solvate)	MEK1, IC₅₀: 2 nM	MEK2, IC₅₀: 2 nM				99.56%
Lidocaine				MEK		99.96%
trans-Zeatin				MEK		99.60%
CI-1040	MEK1, IC₅₀: 17 nM					99.91%
Lixisenatide	MEK1	MEK2				99.93%
Pimasertib	MEK1	MEK2				99.60%
Lidocaine hydrochloride				MEK		99.84%
GDC-0623	MEK1, Ki: 0.13 nM (+ATP)					98.74%
BIX02189			MEK5, IC₅₀: 1.5 nM			99.93%
Trametiglue	MEK1	MEK2				98.81%
Refametinib	MEK1, IC₅₀: 19 nM	MEK2, IC₅₀: 47 nM				99.82%
TERT activator-1	MEK1	MEK2				99.50%
Lidocaine (Standard)				MEK
Tunlametinib	MEK1	MEK2				99.53%
TAK-733				MEK, IC₅₀: 3.2 nM		99.79%
RGB-286638	MEK1, IC₅₀: 54 nM					99.70%
Azelnidipine	MEK1	MEK2				99.79%
AZD8330	MEK1, IC₅₀: 7 nM	MEK2, IC₅₀: 7 nM				99.06%
SL327	MEK1, IC₅₀: 180 nM	MEK2, IC₅₀: 220 nM				99.57%
APS-2-79	MEK1					99.38%
MS432	MEK1, DC₅₀: 31 nM (in HT29 cells) MEK1, DC₅₀: 31 nM (in SK-MEL-28 cells)	MEK2, DC₅₀: 17 nM (in HT29 cells) MEK2, DC₅₀: 9.3 nM (in SK-MEL-28 cells)				99.72%
MAP855	MEK1, IC₅₀: 3 nM					98.48%
RO4987655	MEK1, IC₅₀: 5.2 nM	MEK2, IC₅₀: 5.2 nM				99.01%
GW284543			MEK5			99.94%
PD318088	MEK1	MEK2				99.82%
BIX02188			MEK5, IC₅₀: 4.3 nM			99.85%
BI-847325		MEK2, IC₅₀: 4 nM				98.15%
Zapnometinib				MEK, IC₅₀: 5.7 nM		99.85%
Lidocaine hydrochloride hydrate				MEK		99.90%
Cobimetinib hemifumarate	MEK1, IC₅₀: 4.2 nM					99.73%
RGB-286638 free base	MEK1, IC₅₀: 54 nM					98.87%
PD 198306				MEK		99.75%
Nedometinib	MEK1, IC₅₀: 135 nM					98.25%
MEK inhibitor				MEK		98.35%
Polfurmetinib				MEK		98.69%
PD184161				MEK, IC₅₀: 10-100 nM		98.08%
PD0325901-O-C2-dioxolane	MEK1	MEK2				98.62%
Balamapimod				MEK		99.47%
PD-334581	MEK1					99.72%
Hypothemycin	MEK1, Ki: 17 nM	MEK2, Ki: 38 nM				≥98.0%
E6201	MEK1, IC₅₀: 5.2 nM
Refametinib (R enantiomer)				MEK, EC₅₀: 2-15 nM
CHMFL-EGFR-202	MEK1, IC₅₀: 161 nM					99.75%
APS-2-79 hydrochloride	MEK1
Polfurmetinib hydrate				MEK
MEK/PI3K-IN-2	MEK1, IC₅₀: 352 ± 2 nM
MEK/RAF-IN-1	MEK1, IC₅₀: 28 nM
Isorhamnetin (Standard)	MEK1
MEK/PI3K-IN-1	MEK1, IC₅₀: 124 ± 11 nM
GW284543 hydrochloride			MEK5
MEK1-IN-1	MEK1, : 10.29 nM
MEK4 IN-3					MAP2K4/MEK4, IC₅₀: 78 nM
MEK-IN-1				MEK

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4